SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.
$ALNY
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/4/2025 | Underperform → Peer Perform | Wolfe Research | |
| 8/4/2025 | $490.00 | Perform → Outperform | Oppenheimer |
| 7/30/2025 | $370.00 | Outperform | Raymond James |
| 7/21/2025 | $385.00 | Buy | Truist |
| 3/31/2025 | $353.00 | Buy | Redburn Atlantic |
| 3/24/2025 | $280.00 → $328.00 | Neutral → Overweight | Analyst |
| 11/12/2024 | Peer Perform → Underperform | Wolfe Research | |
| 10/16/2024 | Sector Outperform | Scotiabank |
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular disease and reinforce Alnylam's commitment to advancing innovative therapies for patients living with rare and more prevalent conditions underserved by
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and pre
− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil
10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform
Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00
Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has
As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th
– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi
− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti
− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)